Shares of the clinical-stage biotech Minerva Neurosciences (NASDAQ: NERV) gained as much as 35% in early-morning trading today on sky-high volume. The catalyst that sparked this sizable rally is the news that Minerva and Johnson & Johnson (NYSE: JNJ) have agreed to amend their licensing deal related to the experimental insomnia and major depressive disorder drug candidate MIN-202 (JNJ 42827922).
Image source: Getty Images.